Working… Menu
Trial record 87 of 213 for:    "Hypogonadism" | "Androgens"

Dose Titration Investigation of the Pharmacokinetics of Testosterone Transdermal Systems in Hypogonadal Men

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01104246
Recruitment Status : Completed
First Posted : April 15, 2010
Results First Posted : February 23, 2011
Last Update Posted : October 5, 2012
Information provided by (Responsible Party):
Watson Pharmaceuticals

Brief Summary:
The study will evaluate the pharmacokinetics of testosterone transdermal systems at steady-state in hypogonadal men.

Condition or disease Intervention/treatment Phase
Hypogonadism Drug: Testerone Transdermal System Phase 1

Detailed Description:
Subjects will receive testosterone for 4 weeks. Based on a single morning testosterone measurement performed at the end of Week 1, the dosage can be titrated up or down to the next dose level to maintain testosterone levels in the normal range. At the end of 4 weeks of treatment, a pharmacokinetic profile for total testosterone and metabolites will be obtained.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Dose-Titration Investigation of the Pharmacokinetics, Metabolism and Safety of Testosterone Transdermal Systems in Hypogonadal Men
Study Start Date : April 2010
Actual Primary Completion Date : September 2010
Actual Study Completion Date : September 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Testosterone Transdermal Systems
Drug: Testerone Transdermal System
Transdermal testosterone applied daily for 4 weeks
Other Name: Testosterone

Primary Outcome Measures :
  1. Time-average (Cavg) Steady State Testosterone Concentration Over 24 Hours [ Time Frame: Day 28/29 ]
    A 24-hour pharmacokinetic sampling was performed on Day 28/29 after the start of dosing.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males in good general health, 18 years of age or older.
  • Have a previously documented testosterone deficiency.
  • Willing and able to comply with the requirements of the protocol.

Exclusion Criteria:

  • Have a history of intolerance to Androderm or other testosterone products.
  • Prostate specific antigen (PSA) level ≥ 4.0 ng/mL
  • Prostate cancer or severe benign prostatic hypertrophy (BPH)
  • Have significant abnormalities in the physical examination at screening.
  • Have current dermatological disease, skin damage or blemishes.
  • Have participated in an investigational drug study within 30 days prior to screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01104246

Layout table for location information
United States, Florida
Watson investigational site
Miramar, Florida, United States, 33025
United States, Nebraska
Watson investigational site
Omaha, Nebraska, United States, 68184
United States, Texas
Watson investigational site
San Antonio, Texas, United States, 78209
Sponsors and Collaborators
Watson Pharmaceuticals
Layout table for investigator information
Study Director: Keshava Kumar, PhD, MHSA Watson Laboratories

Layout table for additonal information
Responsible Party: Watson Pharmaceuticals Identifier: NCT01104246     History of Changes
Other Study ID Numbers: AND1001
First Posted: April 15, 2010    Key Record Dates
Results First Posted: February 23, 2011
Last Update Posted: October 5, 2012
Last Verified: October 2012
Keywords provided by Watson Pharmaceuticals:
Hormone replacement therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Gonadal Disorders
Endocrine System Diseases
Testosterone undecanoate
Testosterone enanthate
Testosterone 17 beta-cypionate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents